Table 2.

Relationship between E-cadherin immunoreactivity and clinicopathologic variables/clinical response

E-cadherin positive
E-cadherin negative
All patients
Chemo (n = 37)E + chemo (n = 28)Chemo (n = 14)E + chemo (n = 8)Chemo (n = 540)*E + chemo (n = 539)
Demographics and baseline characteristics
Age (y)
    Mean ± SD62 ± 1063 ± 1470 ± 963 ± 863 ± 1063 ± 10
Gender (%)
    Female13 (35)13 (46)4 (29)6 (75)207 (38)217 (40)
Ethnicity (%)
    White35 (95)26 (93)12 (86)8 (100)482 (89)452 (84)
    Asian1 (3)0 (0)1 (7)0 (0)13 (2)21 (4)
    Others1 (3)2 (7)1 (7)0 (0)44 (8)66 (12)
Smoking history (%)
    Never smokers0 (0)2 (7)1 (7)1 (13)44 (8)72 (13)
ECOG performance status (%)
    012 (32)8 (29)6 (43)2 (25)195 (36)186 (35)
    125 (68)20 (71)8 (57)6 (75)342 (64)353 (66)
    20 (0)0 (0)0 (0)0 (0)1 (0.2)0 (0)
Cancer stage (%)
    IIIB7 (19)3 (11)1 (7)0 (0)96 (18)84 (16)
    IV30 (81)25 (89)13 (93)8 (100)443 (82)455 (84)
Histology (%)
    Adenocarcinoma23 (62)17 (61)8 (57)5 (63)331 (61)323 (60)
    Squamous cell carcinoma8 (22)7 (25)3 (21)1 (13)87 (16)98 (18)
    Others6 (16)4 (14)3 (21)2 (25)121 (22)118 (22)
Months since initial NSCLC diagnosis
    Median1.71.21.72.31.11.1
    Range0-440-1320-350-620-2090-248
Best response, time to progression, and overall survival
Best response
    Response rate5 (13.5)5 (17.9)6 (42.9)2 (25.0)104 (19.3)116 (21.5)
    95% CI for response rate(2.5-24.5)(3.7-32.0)(16.9-68.8)(0.0-55.0)(15.9-22.6)(18.1-25.0)
    P (Fisher's exact)0.73410.64940.4059
Time to progression
    Median time (wk)19.334.030.019.122.323.7
    HR0.371.630.90
    95% CI for HR(0.19-0.73)(0.50-5.33)(0.78-1.05)
    P (log rank)0.00280.39760.1697
Overall survival
    Median time (mo)13.615.111.39.710.510.6
    HR0.821.821.00
    95% CI for HR(0.43, 1.58)(0.60, 5.49)(0.86, 1.16)
    P (log rank)0.56040.28230.9517
  • Abbreviations: E, erlotinib; chemo, chemotherapy; ECOG, Eastern Cooperative Oncology Group.

  • * One patient did not have any baseline information collected. This patient was included in the overall survival analysis only.